Zobrazeno 81 - 90
of 295
pro vyhledávání: ''
Autor:
Carolyn D. Britten, Amarnath Sharma, Anthony W. Tolcher, Feng Guo, Pamela N. Munster, Karen A. Gelmon, Stephen P. Letrent
Publikováno v:
Cancer Chemotherapy and Pharmacology. 62:97-109
CP-724,714 is an orally available, small molecule, potent HER-2 tyrosine kinase inhibitor under development for the treatment of advanced HER2-overexpressing cancers. In this study, the influence of baseline clinical characteristics and pathophysiolo
Autor:
Jim Z. Li, Carolyn D. Britten, Dennis J. Slamon, Fairooz F. Kabbinavar, J. Randolph Hecht, Charles M. Baum, Carlo L. Bello
Publikováno v:
Cancer Chemotherapy and Pharmacology. 61:515-524
Sunitinib, an oral multitargeted tyrosine kinase inhibitor that inhibits VEGFR, PDGFR, FLT3, KIT, and RET, is currently approved for the treatment of imatinib-refractory GIST and advanced renal cell carcinoma at a dose of 50 mg daily for 4 weeks foll
Autor:
Noboru Yamamoto, Tomohide Tamura, Yasuhito Fujisaka, Yasuhide Yamada, Atsushi Horiike, Haruyasu Murakami, Tatsu Shimoyama
Publikováno v:
Cancer Chemotherapy and Pharmacology. 61:489-496
The objectives of this phase I dose-finding study of erlotinib were to investigate the toxicity profile, to confirm the acceptable toxicity of doses up to 150 mg/day, and to assess the pharmacokinetic (PK) profile and antitumor activity in Japanese p
Autor:
Joon Oh Park, Ho Yeong Lim, Hyo Rak Lee, Young Suk Park, Do Hoon Lim, Jeeyun Lee, Seong Ho Choi, Jin Seok Heo, Byeong Bae Park, Won Ki Kang, Keunchil Park, Dong Wook Choi, Kyu Taek Lee, Jong Kyun Lee
Publikováno v:
Cancer Chemotherapy and Pharmacology. 60:489-494
While gemcitabine (GEM) is widely accepted for the treatment of advanced pancreatic cancer, capecitabine (CAP) has shown single agent activity and promising efficacy in combination with GEM. This phase II study was conducted to evaluate the efficacy
Autor:
Wei Wang, Ruiwen Zhang, Muhammad Wasif Saif, Sandra Sellers, Linda Cusimano, Hui Wang, Mao Li
Publikováno v:
Cancer Chemotherapy and Pharmacology. 60:871-882
To determine the maximal tolerated doses (MTD) and dose-limiting toxicities (DLT) of combination of 24-h infusions of gemcitabine and irinotecan in patients with advanced solid tumors. Twenty-four patients with advanced solid tumors received gemcitab
Autor:
David P. Ryan, Jeffrey G. Supko, Robert J. Mayer, Clinton F. Stewart, Janet Dancey, Kate Kinsella, Jeffrey A. Meyerhardt, Craig C. Earle, Peter C. Enzinger, Charles S. Fuchs, Jeffrey W. Clark, Shuji Ogino, Ann Michelini, Joseph Paul Eder, Andrew X. Zhu, Ferdinando D’Amato
Publikováno v:
Cancer Chemotherapy and Pharmacology. 60:661-670
To determine the maximum tolerated doses (MTD), toxicities, efficacy, and pharmacokinetics (PK) of gefitinib combined with irinotecan, 5-fluorouracil (5-FU) and leucovorin (IFL) in patients with previously untreated advanced colorectal cancer.Startin
Publikováno v:
Cancer chemotherapy and pharmacology. 77(5)
The purpose of this analysis was to develop a population pharmacokinetic (PK) model for patritumab, a fully human monoclonal antibody that targets human epidermal growth factor receptor 3. A total of 833 serum concentrations were included in this ana
Autor:
Eric K. Rowinsky, George Hage, Paul I. Nadler, Amita Patnaik, Mark S. Huberman, Julie Wolf, Daniel D. Von Hoff, Tomislav Dragovich, Marta Hamilton, Debra L. Wood
Publikováno v:
Cancer Chemotherapy and Pharmacology. 60:295-303
The purpose of this phase IB trial was to evaluate the tolerability, pharmacokinetics and preliminary evidence of antitumor activity of erlotinib plus gemcitabine in patients with pancreatic cancer and other solid tumors.Patients included those with
Autor:
Masafumi Kawamura, Teruaki Koike, Keisuke Eguchi, Yasushi Yamato, Enjo Hada, Hirozo Sakaguchi, Yotaro Izumi, Koichi Kobayashi
Publikováno v:
Cancer Chemotherapy and Pharmacology. 60:495-501
Few clinical phase II studies using non-platinum doublet as adjuvant chemotherapy following complete resection of non-small-cell lung cancer (NSCLC) have been published, so this clinical study was designed to evaluate the toxicity profile and efficac
Autor:
Etienne Chatelut, Henri Roché, Isabelle Lochon, Florent Puisset, Jean-Pierre Delord, D. Berchery, Alex Sparreboom, Thierry Lafont
Publikováno v:
Cancer Chemotherapy and Pharmacology. 60:305-308
A study was conducted to evaluate prospectively the correlation between docetaxel clearance and pharmacokinetics of dexamethasone previously obtained in 21 patients.Dexamethasone pharmacokinetics were performed in 17 patients 24 h before docetaxel tr